ETF recommends updating COVID-19 vaccines to target XFG variant

EMA Recommends Updating COVID-19 Vaccines to Target XFG Variant

The European Medicines Agency's (EMA) Emergency Task Force (ETF) has recommended updating COVID-19 vaccines to target the SARS-CoV-2 XFG variant for the 2026/2027 vaccination campaign. This recommendation, issued on May 29, 2026, aims to maintain protection as the virus evolves. The XFG variant, part of the JN.1 family of Omicron subvariants, peaked at 74% of global infections in October 2025. The ETF consulted with the World Health Organization and considered extensive data on viral evolution, vaccine effectiveness against JN.1/KP.2 and LP.8.1 strains, and animal study results for XFG-, LP.8.1-, and BA.3.2.2-adapted candidates. The evidence suggests XFG targeting offers the best protection against JN.1 omicron subvariants and BA.3.2.

• The EMA's Emergency Task Force (ETF) has formally recommended that COVID-19 vaccines be updated to specifically target the XFG variant for the upcoming 2026/2027 vaccination season. The XFG variant, identified as a subvariant within the JN.1 family of Omicron, has shown significant global circulation, reaching a peak prevalence of 74% of genetically sequenced infections worldwide by October 2025. This strategic update is crucial for ensuring continued vaccine efficacy against the dominant circulating strains and maintaining public health protection.
• The ETF's recommendation is based on a comprehensive review of scientific data, including the latest insights into viral evolution, the effectiveness of current vaccines containing JN.1/KP.2 and LP.8.1 strains, and findings from animal studies on candidate vaccines adapted to XFG, LP.8.1, and BA.3.2.2. The collective evidence strongly indicates that targeting the XFG variant will provide optimal protection against COVID-19 caused by JN.1 omicron subvariants and also offer cross-protection against the BA.3.2 variant, which is also increasing in circulation.
• Following this recommendation, marketing authorisation holders for COVID-19 vaccines are now instructed to engage with the EMA to discuss the necessary updates to their vaccine compositions. Companies developing new vaccines targeting other strains are also encouraged to consult with the EMA regarding potential changes. Ultimately, national authorities within the European Union will make the final decisions regarding their respective vaccination campaigns for 2026 and 2027, taking into account their specific epidemiological situations.

Addressing the Evolving Challenge of COVID-19 Variants

Current COVID-19 treatment approaches face substantial barriers that limit their effectiveness and accessibility across diverse healthcare settings. These challenges span from fundamental research limitations to inequitable distribution of therapeutic benefits globally. The landscape reveals significant gaps in both drug development investment and treatment accessibility, particularly affecting vulnerable populations and resource-constrained environments.

• Limited therapeutic development investment - COVID-19 therapeutics have received substantially less investment compared to vaccines, resulting in few high-quality published studies, low trial completion rates, and predominantly negative results across clinical investigations

• Inadequate coordination in accessible treatment trials - Low- and middle-income countries lack proper coordination for trials involving accessible therapeutic agents and their combinations, hindering development of treatments suitable for resource-limited settings

• Healthcare capacity-dependent efficacy - The impact of established treatments like dexamethasone varies dramatically by healthcare infrastructure, potentially averting 22% of deaths in high-income countries but only 8% in low-income countries due to limited supportive care availability

• Absence of effective commercial antivirals - As of 2024, no commercially available effective antiviral therapies exist for COVID-19, creating an urgent need for novel therapeutic modalities beyond current treatment options

• Resource allocation challenges in developing countries - Low- and middle-income countries face significant obstacles in COVID-19 control due to limited healthcare resources, particularly for inpatient care and specialized treatments requiring oxygen or mechanical ventilation

• Health equity gaps in pandemic response - Healthcare inequalities have been exacerbated for vulnerable populations, with over 70% of autistic individuals losing everyday support due to care interruptions, and discriminatory ICU triage protocols excluding certain groups from lifesaving treatments

• Nanotechnology implementation barriers - Novel nanotechnology-based therapeutic approaches face challenges including associated toxicity concerns, lengthy clinical trial procedures, and uncertain long-term health risks that complicate regulatory approval and clinical adoption

The Evidence Supporting XFG Vaccine Update

Recent clinical trials for COVID-19 have employed diverse study designs ranging from traditional randomized controlled trials to innovative platform trials and seamless phase II/III studies. The trials have evaluated various therapeutic interventions including antivirals, monoclonal antibodies, immunomodulators, and repurposed drugs, with endpoints focused on clinical recovery, viral clearance, and safety outcomes.

Implications for COVID-19 Vaccine Developers and Market

The COVID-19 treatment landscape has undergone substantial evolution from the early pandemic period through 2025, characterized by rapid therapeutic development, regulatory approvals, and subsequent real-world implementation challenges. The initial period in 2020 saw over 1,900 clinical trials registered globally, primarily focused on hospitalized patients with advanced disease. During this early phase, case mortality rates decreased dramatically by 80-90% across the US and Europe between April and June 2020, though effective therapies for severe COVID-19 remained unavailable. The treatment paradigm initially missed opportunities for early pharmaceutical interventions that could have addressed not only morbidity and mortality but also transmissibility.

The period from 2021-2022 marked a critical turning point with the emergency authorization of four key medications for outpatient treatment of mild-to-moderate COVID-19 in high-risk patients: nirmatrelvir/ritonavir (Paxlovid), molnupiravir (Lagevrio), expanded remdesivir use, and bebtelovimab. Paxlovid emerged as the dominant therapy, with utilization increasing from 0.6% in January 2022 to 34.3% by July 2022 among patients seeking medical care, while other authorized treatments achieved lower adoption rates of 0.7%-5.0%. However, real-world outcomes in the UK demonstrated treatment disparities, with only 33.2% of referred patients suitable for assessment and COVID-19-related hospitalizations occurring in 1.2% of treated versus 3.0% of untreated patients—rates lower than those reported in original clinical trials.

By 2024-2025, the treatment approach evolved into a more stratified strategy utilizing primarily antiviral and immunomodulatory agents based on disease severity. Antivirals including remdesivir and nirmatrelvir-ritonavir proved most beneficial for early illness and outpatient therapy, while immunomodulatory treatments such as dexamethasone and interleukin-6 or Janus kinase inhibitors demonstrated greatest utility in severe disease or critical illness. Despite these therapeutic advances, concerning trends emerged including persistent racial and ethnic disparities in treatment access, with Black patients receiving Paxlovid 35.8% less often than White patients during 2022. Most notably, recent 2025 data revealed that 30-day mortality for critically ill COVID-19 ICU patients remained unchanged between early pandemic and post-vaccine periods (30% versus 37% mortality), with 81% of ICU patients in the later period remaining unvaccinated, highlighting the complex interplay between therapeutic advances and vaccination status in determining clinical outcomes.

EMA's XFG Recommendation: Navigating the Evolving COVID-19 Landscape

The European Medicines Agency's Emergency Task Force recommendation to update COVID-19 vaccines for the 2026/2027 campaign, specifically targeting the XFG variant, marks a significant juncture in our ongoing battle against SARS-CoV-2. This decision, grounded in comprehensive data on viral evolution and vaccine effectiveness, underscores the virus's relentless capacity for genetic diversification and immune evasion, particularly within the Omicron lineage, of which XFG is a JN.1 subvariant.

For the pharmaceutical industry, this signals a clear strategic imperative: the era of static COVID-19 vaccines is over. Companies must now fully embrace agile vaccine development platforms that can rapidly pivot to address emerging variants. This move solidifies a seasonal, influenza-like model for COVID-19 vaccination, demanding that manufacturers optimize their supply chains and production capabilities for annual variant-specific updates. Furthermore, sustained investment in global genomic surveillance and real-time effectiveness studies is paramount. This intelligence will be crucial for anticipating future variant trends and informing the design of next-generation vaccines, including potential pan-variant or universal candidates.

However, this adaptive strategy is not without its challenges. A primary risk is the continuous emergence of novel SARS-CoV-2 variants. Despite targeting XFG, the virus's rapid mutation rate, especially in the spike protein, means that new sub-lineages could quickly arise and evade the updated vaccine, as evidenced by previous Omicron variants demonstrating reduced neutralization and limited boosting of humoral immunity against subsequent strains. Another critical consideration is the persistent issue of global vaccine equity. Historical data consistently shows stark disparities in vaccine access and uptake between high-income and low-income countries. If not addressed, these inequities could undermine the global impact of an XFG-adapted vaccine campaign, potentially creating reservoirs for new variant emergence. Finally, the challenge of waning immunity and potential 'booster fatigue' among the public remains. While booster doses are essential to maintain protection, repeated calls for updated vaccinations could lead to decreased adherence, leaving populations vulnerable to future waves. Addressing these risks will require not only scientific innovation but also robust public health communication and equitable distribution strategies.